0100 Europe 2026: The Private Markets Event Where LP Checks Actually Get Discussed
The 0100 Europe gathering on April 21–23 remains one of Europe's most pragmatic venues for GP-LP relationships and private markets deal talk.
investment-strategies
-
-
Slush 2026 Preview: Helsinki's November Summit Is Still Europe's Single Biggest VC Weekend
With 13,000+ attendees and 500+ LPs expected in Helsinki, Slush 2026 remains the gravity center of European venture deal-making.
-
NYC Early-Stage Venture in 2026: Who's Writing Seed Checks Today
A pragmatic 2026 map of NYC's most active seed and pre-seed investors — and what they actually fund.
-
BDC Capital's $150M Life Sciences Fund: Canada's Medtech Layer Gets Capital
BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.
-
Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
-
KKR's $23B North America PE Fund: Scale Capital Reshapes the Growth-Stage VC Market
Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.